Houillier et al. studied 171 patients without adjuvant therapies until first progression and demonstrated that spontaneous PFS did not differ significantly in patients with IDH mutated and wild-type low-grade gliomas [14]. This evidence concerns the gene IDH2 and central nervous system cancer.